Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KER-065 · 1 trial · 1 indication
To evaluate the safety and tolerability of KER-065 in ambulatory and nonambulatory participants with DMD
| Arm | Type | Description |
|---|---|---|
| Cohort A1 (Late Ambulatory) | EXPERIMENTAL | Participants will receive stable corticosteroid (CS) along with KER-065. |
| Cohort A2 (Late Ambulatory) | EXPERIMENTAL | Participants will receive stable CS, exon skipper along with KER-065. |
| Cohort N1 (Nonambulatory) | EXPERIMENTAL | Participants will receive stable CS along with KER-065. |
| Name | Type | Description |
|---|---|---|
| KER-065 | DRUG | KER-065 will be administered subcutaneously (SC) |
Key Inclusion Criteria: * Diagnosis of DMD, defined as the presence of phenotypic features at screening consistent with DMD AND documented mutation in the dystrophin gene consistent with the diagnosis of DMD using a clinically validated genetic test. * Receiving a stable regimen of systemic CS (inc...